id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA_FRDOC_0001-12138,FDA,FDA_FRDOC_0001,"Agency InformationCollection Activities; Proposals, Submissions, and Approvals: Food Labeling Requirements",Notice,,2023-04-12T04:00:00Z,2023,4,2023-04-12T04:00:00Z,2023-06-13T03:59:59Z,2023-04-12T12:12:35Z,2023-07683,0,0,09000064859343c2
FDA_FRDOC_0001-12140,FDA,FDA_FRDOC_0001,Final Debarment Order: Olga L. Torres,Notice,,2023-04-12T04:00:00Z,2023,4,2023-04-12T04:00:00Z,,2023-04-12T12:13:58Z,2023-07670,0,0,0900006485934577
FDA_FRDOC_0001-12139,FDA,FDA_FRDOC_0001,Guidance for Industry: A Risk-Based Approach to Monitoring of Clinical Investigations—Questions and Answers,Notice,,2023-04-12T04:00:00Z,2023,4,2023-04-12T04:00:00Z,,2023-04-12T12:13:25Z,2023-07687,0,0,09000064859344b8
FDA_FRDOC_0001-12120,FDA,FDA_FRDOC_0001,Guidance: Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making,Notice,,2023-04-06T04:00:00Z,2023,4,2023-04-06T04:00:00Z,2023-07-06T03:59:59Z,2023-04-06T13:34:46Z,2023-07243,0,0,09000064858f20e2
FDA_FRDOC_0001-12122,FDA,FDA_FRDOC_0001,"Guidance: Permanent Discontinuance or Interruption in Manufacturing under the Federal Food, Drug, and Cosmetic Act",Notice,,2023-04-06T04:00:00Z,2023,4,2023-04-06T04:00:00Z,2023-06-06T03:59:59Z,2023-04-06T13:36:02Z,2023-07238,0,0,09000064858f226f
FDA_FRDOC_0001-12123,FDA,FDA_FRDOC_0001,Guidance: Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development,Notice,,2023-04-06T04:00:00Z,2023,4,2023-04-06T04:00:00Z,2023-05-16T03:59:59Z,2023-04-08T01:01:34Z,2023-07185,0,0,09000064858f22cb
FDA_FRDOC_0001-12121,FDA,FDA_FRDOC_0001,Guidance: Action Levels for Lead in Food Intended for Babies and Young Children,Notice,,2023-04-06T04:00:00Z,2023,4,2023-04-06T04:00:00Z,2023-05-09T03:59:59Z,2023-04-06T13:35:24Z,2023-07187,0,0,09000064858f2164